Skip to main content
SpringerLink
Log in

Certolizumab Pegol in Crohn’s Disease

A Viewpoint by Trevor A. Winter

  • Adis Drug Profile
  • Guest Commentary
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002 May 4; 359(9317): 1541–9

    Article  PubMed  CAS  Google Scholar 

  2. Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab induces and maintains clinical response and remission in patients with active Crohn’s disease: results of the CHARM trial. Gastroenterology 2006; 131(3): 950

    Article  Google Scholar 

  3. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005 Sep; 129(3): 807–18

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Digestive Diseases and Nutrition, University of Kentucky, Lexington, Kentucky, USA

    Trevor A. Winter

Authors
  1. Trevor A. Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winter, T.A. Certolizumab Pegol in Crohn’s Disease. BioDrugs 21, 202 (2007). https://doi.org/10.2165/00063030-200721030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721030-00007

Keywords

Search

Navigation